278 related articles for article (PubMed ID: 34489691)
1. Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study.
Sun Y; Jiang L; Wen T; Guo X; Shao X; Qu H; Chen X; Song Y; Wang F; Qu X; Li Z
Front Pharmacol; 2021; 12():670900. PubMed ID: 34489691
[TBL] [Abstract][Full Text] [Related]
2. Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis.
Liu Y; Xu Y; Cheng X; Lin Y; Jiang S; Yu H; Zhang Z; Lu L; Zhang X
Front Immunol; 2022; 13():862084. PubMed ID: 35493449
[TBL] [Abstract][Full Text] [Related]
3. PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy.
Liu J; Chen Z; Li Y; Zhao W; Wu J; Zhang Z
Front Pharmacol; 2021; 12():731798. PubMed ID: 34539412
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.
Zuazo M; Gato-Cañas M; Llorente N; Ibañez-Vea M; Arasanz H; Kochan G; Escors D
Ann Transl Med; 2017 Oct; 5(19):385. PubMed ID: 29114543
[TBL] [Abstract][Full Text] [Related]
5. Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy.
Weidhaas J; Marco N; Scheffler AW; Kalbasi A; Wilenius K; Rietdorf E; Gill J; Heilig M; Desler C; Chin RK; Kaprealian T; McCloskey S; Raldow A; Raja NP; Kesari S; Carrillo J; Drakaki A; Scholz M; Telesca D
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35115362
[TBL] [Abstract][Full Text] [Related]
6. Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis.
Liu Y; Cheng X; Han X; Cheng X; Jiang S; Lin Y; Zhang Z; Lu L; Qu B; Chen Y; Zhang X
Front Immunol; 2022; 13():1032747. PubMed ID: 36532038
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant Therapy With PD1/PDL1 Inhibitors for Human Cancers: A Systematic Review and Meta-Analysis.
Jin Y; Wei J; Weng Y; Feng J; Xu Z; Wang P; Cui X; Chen X; Wang J; Peng M
Front Oncol; 2022; 12():732814. PubMed ID: 35280727
[TBL] [Abstract][Full Text] [Related]
8. Macrocyclic Compounds from Ansamycin Antibiotic Class as Inhibitors of PD1-PDL1 Protein-Protein Interaction.
Patil SP; Yoon SC; Aradhya AG; Hofer J; Fink MA; Enley ES; Fisher JE; Herb MC; Klingos A; Proulx JT; Fedorky MT
Chem Pharm Bull (Tokyo); 2018; 66(8):773-778. PubMed ID: 30068796
[TBL] [Abstract][Full Text] [Related]
9. [Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].
Guilleminault L; Carmier D; Heuzé-Vourc'h N; Diot P; Pichon E
Rev Pneumol Clin; 2015 Feb; 71(1):44-56. PubMed ID: 25687821
[TBL] [Abstract][Full Text] [Related]
10. Bispecific Aptamer-Based Recognition-then-Conjugation Strategy for PD1/PDL1 Axis Blockade and Enhanced Immunotherapy.
Sun Y; Mo L; Hu X; Yu D; Xie S; Li J; Zhao Z; Fang X; Ye M; Qiu L; Tan W; Yang Y
ACS Nano; 2022 Dec; 16(12):21129-21138. PubMed ID: 36484532
[TBL] [Abstract][Full Text] [Related]
11. Proton beam radiotherapy combined with anti-PD1/PDL1 immune checkpoint inhibitors for advanced hepatocellular carcinoma.
Su CW; Hou MM; Huang PW; Chou YC; Huang BS; Tseng JH; Hsu CW; Chang TC; Lin SM; Lin CC
Am J Cancer Res; 2022; 12(4):1606-1620. PubMed ID: 35530291
[TBL] [Abstract][Full Text] [Related]
12. Global research landscape and trends of cancer radiotherapy plus immunotherapy: A bibliometric analysis.
Liu Y; Jiang X; Wu Y; Yu H
Heliyon; 2024 Mar; 10(5):e27103. PubMed ID: 38449655
[TBL] [Abstract][Full Text] [Related]
13. The Prognostic Significance of PD1 and PDL1 Gene Expression in Lung Cancer: A Meta-Analysis.
Chang CH; Shih AC; Chang YH; Chen HY; Chao YT; Hsu YC
Front Oncol; 2021; 11():759497. PubMed ID: 34868974
[TBL] [Abstract][Full Text] [Related]
14. Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy.
Luo K; Liu S; Shen X; Xu J; Shi C; Chao Y; Wen Z; Zhang K; Wang R; Liu B; Jiang Y
Front Cell Dev Biol; 2022; 10():1003656. PubMed ID: 36467413
[No Abstract] [Full Text] [Related]
15. Research landscape and trends of melanoma immunotherapy: A bibliometric analysis.
Liu Y; Yu L; Liang Y; Cheng X; Jiang S; Yu H; Zhang Z; Lu L; Qu B; Chen Y; Zhang X
Front Oncol; 2022; 12():1024179. PubMed ID: 36698407
[TBL] [Abstract][Full Text] [Related]
16. VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma.
Jlassi A; Rejaibi R; Manai M; Sahraoui G; Guerfali FZ; Charfi L; Mezlini A; Manai M; Mrad K; Doghri R
Front Oncol; 2024; 14():1352053. PubMed ID: 38634058
[TBL] [Abstract][Full Text] [Related]
17. Expression of PD1/PDL1 in gastric cancer at different microsatellite status and its correlation with infiltrating immune cells in the tumor microenvironment.
Wang YL; Gong Y; Lv Z; Li L; Yuan Y
J Cancer; 2021; 12(6):1698-1707. PubMed ID: 33613757
[No Abstract] [Full Text] [Related]
18. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and anti-angiogenic therapy for solid tumors: A systematic review and meta-analysis.
Xian F; Wu J; Zhong L; Xu G
Medicine (Baltimore); 2023 Mar; 102(10):e33204. PubMed ID: 36897735
[TBL] [Abstract][Full Text] [Related]
20. Machine-Learning Guided Discovery of Bioactive Inhibitors of PD1-PDL1 Interaction.
Patil SP; Fattakhova E; Hofer J; Oravic M; Bender A; Brearey J; Parker D; Radnoff M; Smith Z
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
